LUCD - NASDAQ

Lucid Diagnostics Inc.

LUCD·NASDAQ

$1.02

+0.49%

HealthcareMedical - Devices

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$104.35M

EPS-0.6900

P/E Ratio-1.48

Earnings Date08/12/2026

-46.48B

Operating Cash Flow

105213%

3Y+156494.0%

5Y+825764.0%

10Y+40883805.0%

-197.00M

Investing Cash Flow

30395%

3Y+4696.0%

5Y-

10Y-

59.03B

Financing Cash Flow

122245%

3Y+2260681.0%

5Y+1057104.0%

10Y+44888873.0%

Lucid Diagnostics Inc. Cash Conversion Engine

LUCD · NASDAQ

FCF Components

Net Income-58.01B

Depreciation & Amortization872.00M

Stock-Based Compensation4.39B

Change in Working Capital-2.81M

Others6.27B

Capital Expenditures-197.00K

Free Cash Flow-46.48B

Cash Flow Quality Analysis

FCF Conversion Rate

80.1%

Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.

CapEx Intensity

-0.0%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

-103693.6%

Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.

Working Capital Impact

-$2.81M

Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.

Cash Flow Quality Insight

Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.

Lucid Diagnostics Inc. Cash Flow Statement

LUCD • NASDAQ

Lucid Diagnostics Inc. Cash Flow Statement	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
OPERATING ACTIVITIES
Net Income	-58B	-45.5M	-52.7M	-56.2M	-28.1M	-8.3M	-4.4M	-1.1M
Depreciation & Amortization	872M	1.2M	2.5M	1.9M	4K	0.0	0.0	0.0
Stock-Based Compensation	4.4B	4.5M	6.8M	15M	9.6M	65K	173.9K	79.9K
Other Non-Cash Items	6.3B	119K	4.9M	653K	0.0	459.0	0.0	-205.1K
Change in Working Capital	-2.8M	-4.4M	5.7M	8.9M	807K	2.6M	1.9M	720.1K
Cash from Operating Activities	-46.5B	-44.1M	-32.8M	-29.7M	-17.7M	-5.6M	-2.4M	-113.7K
INVESTING ACTIVITIES
Investments in Property, Plant, and Equipment	-197K	-296K	-221K	-908K	-862K	(0.0)	(0.0)	(0.0)
Other Investing Items	-196.8M	-350K	0.0	-3.2M	0.0	0.0	0.0	0.0
Cash from Investing Activities	-197M	-646K	-221K	-4.1M	-862K	(0.0)	(0.0)	(0.0)
FINANCING ACTIVITIES
Net Issuance of Common Stock	58.7M	0.0	284K	1.8M	77.7M	5.6M	0.0	0.0
Net Issuance of Debt	360K	18M	10M	0.0	0.0	0.0	0.0	0.0
Other Financing Items	59B	451K	551K	804K	-5.7M	0.0	2.5M	131.5K
Cash from Financing Activities	59B	48.2M	29.5M	2.6M	72.1M	5.6M	2.5M	131.5K
CASH FLOW SUMMARY
Effect of Foreign Exchange Rates	0.0	0.0	0.0	0.0	-255.0	0.0	0.0	0.0
Net Change in Cash	12.3B	3.5M	-3.6M	-31.2M	53.5M	-45.1K	138.6K	17.8K
Cash at Beginning of Period	22.4B	18.9M	22.5M	53.7M	111.3K	156.4K	17.8K	0.0
Cash at End of Period	34.7B	22.4M	18.9M	22.5M	53.7M	111.3K	156.4K	17.8K
Free Cash Flow	-46.5B	-44.8M	-33M	-30.6M	-18.5M	-5.6M	-2.4M	-113.7K

SEC Filings

LUCD - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 14, 2026	May 14, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 30, 2026	April 30, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 24, 2026	April 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 23, 2026	April 23, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 26, 2026	March 26, 2026	2026	View Filing
S-3/A S-3/A (Amended) N/A	March 26, 2026	March 26, 2026		View Filing
10-K 10-K 2025 FY FY	March 25, 2026	December 31, 2025	2025	View Filing
S-3 S-3 N/A	December 05, 2025	December 05, 2025		View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 105 filings

Related Guides

Blog Categories

Continue your LUCD research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.